Proteon logo     Print Page | Close Window

SEC Filings

S-1/A
PROTEON THERAPEUTICS INC filed this Form S-1/A on 10/07/2014
Entire Document
 

Table of Contents

 

 
  As of June 30, 2014  
 
  Actual   Pro Forma(2)   Pro Forma
As Adjusted(3)(4)(5)
 
 
  (unaudited)
(in thousands)

 

Balance Sheet Data:

                   

Cash, cash equivalents and available-for-sale investments

  $ 25,416   $ 25,416   $ 79,914  

Working capital

    19,915     19,915     75,325  

Total assets

    27,142     27,142     80,446  

Preferred stock

    123,904          

Common stock and additional paid in capital

    0     123,904     178,121  

Total stockholders' (deficit) equity

    (109,290 )   21,194     75,411  

(1)
See Note 2 within the notes to our financial statements appearing elsewhere in this prospectus for a description of the method used to calculate basic and diluted net loss per common share and pro forma basic and diluted net loss per common share.

(2)
Pro forma to reflect the conversion of all outstanding shares of our preferred stock into shares of common stock upon the closing of this offering and the extinguishment of the liability related to the Series D investors' purchase rights.

(3)
Pro forma as adjusted to reflect the pro forma adjustments described in (2) above, and to further reflect (i) the filing and effectiveness of our amended and restated certificate of incorporation, which will occur immediately prior to the closing of this offering and (ii) the sale of shares of our common stock offered in this offering, assuming an initial public offering price of $13.00 per share, the midpoint of the price range set forth on the cover page of this prospectus, after deducting underwriting discounts and commissions and estimated offering expenses payable by us.

(4)
A $1.00 increase (decrease) in the assumed initial public offering price of $13.00 per share, the midpoint of the price range set forth on the cover of this prospectus, would increase (decrease) the pro forma as adjusted amount of each of cash and cash equivalents, working capital, total assets, common stock and additional paid-in-capital and total stockholders' (deficit) equity by approximately $4.4 million, assuming that the number of shares offered by us, as set forth on the cover of this prospectus, remains the same and after deducting underwriting discounts and commissions and estimated offering expenses payable by us.

(5)
A 1,000,000 share increase in the number of shares offered by us together with a concomitant $1.00 increase in the assumed initial public offering price of $13.00 per share, the midpoint of the price range set forth on the cover of this prospectus, would increase the pro forma as adjusted amount of each of cash and cash equivalents, and total stockholders' (deficit) equity by approximately $17.4 million, after deducting underwriting discounts and commissions and estimated offering expenses payable by us.

 

11